Informações:
Falhas:
ID
14455
Descrição
Phase IIb Randomized Controlled Study of BLP25 Liposome Vaccine for Immunotherapy of Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00157209
Link
https://clinicaltrials.gov/show/NCT00157209
Palavras-chave
Versões (1)
- 15/04/2016 15/04/2016 -
Transferido a
15 de abril de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Lung Neoplasms NCT00157209
Eligibility Lung Neoplasms NCT00157209
- StudyEvent: Eligibility
Similar models
Eligibility Lung Neoplasms NCT00157209
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
NSCLC staging
Item
stage iiib or stage iv nsclc
boolean
C0278984 (UMLS CUI [1])
C0278987 (UMLS CUI [2])
C0278987 (UMLS CUI [2])
Treatment details
Item
stable disease or a clinical response following first-line treatment, consisting of either chemotherapy alone or chemotherapy and radiotherapy. patients must have completed the first-line treatment at least 3 weeks prior to study entry
boolean
C1704632 (UMLS CUI [1])
C1708063 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C3839414 (UMLS CUI [4])
C0580352 (UMLS CUI [5])
C1708063 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C3839414 (UMLS CUI [4])
C0580352 (UMLS CUI [5])
ECOG performance status
Item
ecog performance status of ≤2
boolean
C1520224 (UMLS CUI [1])
Informed consent
Item
ability to understand and willingness to sign a written informed consent
boolean
C0021430 (UMLS CUI [1])
Immunotherapy: date
Item
received immunotherapy within 4 weeks prior to study entry
boolean
C0021083 (UMLS CUI [1])
C2584899 (UMLS CUI [2])
C2584899 (UMLS CUI [2])
Immunosupression: date
Item
received immunosuppressive drugs within 3 weeks prior to study entry
boolean
C0021079 (UMLS CUI [1,1])
C2584899 (UMLS CUI [1,2])
C2584899 (UMLS CUI [1,2])
Brain metastases
Item
patients with known brain metastases
boolean
C0220650 (UMLS CUI [1])
Further malignancies
Item
past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
boolean
C0006826 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0007114 (UMLS CUI [1,3])
C0006826 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C2216722 (UMLS CUI [2,3])
C0006826 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C0242793 (UMLS CUI [3,3])
C0332196 (UMLS CUI [1,2])
C0007114 (UMLS CUI [1,3])
C0006826 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C2216722 (UMLS CUI [2,3])
C0006826 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C0242793 (UMLS CUI [3,3])
Autoimmune disease or immunodeficiency
Item
autoimmune disease or immunodeficiency
boolean
C0004364 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
C0021051 (UMLS CUI [2])
Liver, renal and cardiac function
Item
clinically significant hepatic, renal or cardiac dysfunction
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232164 (UMLS CUI [3])
C0232804 (UMLS CUI [2])
C0232164 (UMLS CUI [3])
Infection
Item
patients with clinically significant active infection
boolean
C0009450 (UMLS CUI [1])
Gynaecological status
Item
pregnant or breast feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator
boolean
C0032961 (UMLS CUI [1])
C3831118 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
C3831118 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
C0700589 (UMLS CUI [4])